Boundless Bio, Inc. has disclosed a significant stock purchase by Kevin Tang, a major stakeholder in the company. On October 27, 2026, Tang acquired 10,707 shares of Boundless Bio's common stock at an average price of $2.40 per share. This transaction is noteworthy as it reflects Tang's confidence in the company's prospects.

Background

Boundless Bio, Inc. operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol BOLD. It is categorized as a non-accelerated filer, smaller reporting company, and an emerging growth company. Recent filings include various forms, with the most recent being a Form 4 filed on October 29, 2026.

What the Filing Says

The recent filing indicates that Kevin Tang purchased the shares on October 27, 2026, with a total of 10,707 shares acquired. Following this transaction, Tang owns a total of 3,022,456 shares of Boundless Bio. The filing notes, "The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.38 to $2.40."

Impact

This purchase may influence investor sentiment regarding Boundless Bio, particularly as Tang is also the sole manager of Tang Capital Management LLC, which holds substantial shares in the company. The transaction highlights the ongoing activity in the pharmaceutical preparations industry, where insider trading can signal confidence or concerns about a company's future performance.

What's Next

The filing does not say what happens next.